MedTrace Logo

Assessment of Neonatal Hyperbilirubinemia by NeoprediX B.1 Algorithm

NCT05121311 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 455

Last updated 2022-05-03

No results posted yet for this study

Summary

Due to actual standard of neonatal care bilirubin is monitored in neonates several times after birth to avoid hyperbilirubinemia. As the peak is often one or two days after discharge from hospital a more precise predication than the actual one is desirable to avoid needlessly follow-ups. The precision of an algorithm to predict bilirubin values 24-48h into the future is evaluated in this study.

Conditions

  • Newborn Jaundice

Interventions

DIAGNOSTIC_TEST

NeoprediX B1 algorithm

Re-assessement of bilirubin measurements done according to standard of care of the participating center by the NeoprediX B1 algorithm

Sponsors & Collaborators

  • Center for Pediatric Clinical Studies (CPCS)

    collaborator UNKNOWN

  • NeoPredix AG

    lead INDUSTRY

Principal Investigators

  • Axel Franz, Prof. · University Children's Hospital Tübingen

Eligibility

Max Age
72 Hours
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-09
Primary Completion
2021-11-30
Completion
2022-01-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05121311 on ClinicalTrials.gov